Tracking a new lymphoma Drug's Real-World performance
Disease control
Ongoing
This study is observing how well the drug epcoritamab works for patients with an aggressive type of lymphoma (DLBCL) that has returned or stopped responding to other treatments. It follows 150 patients in Italy who are already receiving the drug through a special access program, …
Sponsor: Andrés José Maria Ferreri • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC